The Elasticity of Pharmaceutical Innovation – Healthcare Economist


That’s the title of a brand new USC white paper by Darren Filson, Karen Van Nuys, Darius Lakdawalla and Dana Goldman with the subtitle “How A lot Does Income Drive New Drug Improvement?

What’s the elasticity of innovation?

It measures the share change in innovation—utilizing the circulate of latest medication approvals, or Section 1, 2, or 3 begins— attributable to a proportion change in revenues, usually anticipated
future revenues.

In follow, it’s change in earnings that issues, however future revenues are far more observable and predictable than future earnings. Thus, the authors give attention to the elasticity of innovation with respect to income reasonably than earnings.

How a lot do future revenues influence the probability of latest drug growth?

All of the research conclude that the elasticity is constructive—i.e., decrease revenues result in much less R&D— however estimates fluctuate extensively. Nonetheless, we argue {that a} typical long-run elasticity related to U.S. revenues lies throughout the vary of 0.25 to 1.5, implying that for each 10% discount in anticipated revenues, we are able to count on 2.5% to fifteen% much less pharmaceutical innovation.

What’s driving the variability in these estimates?

One key query is why there may be such a wide range in these estimates? Definitely completely different research designs matter (see under). The authors additionally declare that elements equivalent to “the time horizon studied, the scale of the value change, value of drug growth, boundaries to value-based pricing, and different market elements” all influence the magnitude of the elasticity of innovation.

What methodologies are used within the literature to estimate the elasticity of innovation?

  • Cross sectional: exploit variation in revenues throughout therapeutic courses (or another unit of research) to estimate the elasticity. As an illustration, they could evaluate “high-revenue” vs. “low-revenue” courses to deduce the elasticity [Examples: Lichtenberg (2005) and Civan and Maloney (2009)].
  • Mixture time sequence: exploit variation in industry-level revenues over time [Example: Giaccotto, Santerre and Vernon (2005)]
  • Panel information approaches: embrace drug-class “mounted results” and internet out hard-to-measure and protracted variations in school traits. In essence, this strategy strategy focuses on within-class income change as a driver of within-class innovation adjustments. These analyses usually require the usage of “pure experiments” that trigger a differential change in income throughout completely different segments of the market. Examples of pure experiments embrace future demographic adjustments or the arrival of Medicare Half D. [Examples: Acemoglu and Linn (2004); Dubois et al. (2015); Blume-Kohout and Sood (2013)]
  • Parameterized computational fashions (aka structural fashions): specify corporations’ goal features, technique units and options of the enterprise setting, and when the mannequin consists of a number of corporations, the mannequin usually requires that the market is in equilibrium. Parameters are chosen to match these in the actual world (e.g., common R&D bills) and calibrated such that the mannequin outputs additionally match real-world outcomes (e.g., common circulate of latest medication). [Examples: Abbott and Vernon (2007); Filson (2012); Adams (2021)]

The authors argue that panel approaches and parameterized computational fashions are most well-liked.

For the research with the popular panel or computation strategy, which particular person elasticity of innovation estimates did they arrive at?

The authors have a pleasant desk summarizing the findings which I pasted under.

https://schaeffer.usc.edu/wp-content/uploads/2025/02/2025-02-pharmaceutical-innovation.pdf

Nice work by my colleagues at USC! I actually encourage you to learn the total article right here.

Recent Articles

Related Stories

Leave A Reply

Please enter your comment!
Please enter your name here